FOLH1 and prostate cancer: Hope et al. [28] in their prospective multicenter single-arm phase 3 trial of 277 patients with high-risk prostate cancer with Ga68-PSMA-11 PET prior to prostatectomy, 27% of patients were positive for pelvic lymph node metastasis with sensitivity of 40%, specificity of 95%, positive predictive value of 75%, and negative predictive value of 81%.